Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells

Urology

Volumn 78, Issue 1, 2011, Pages 233.e7-233.e13

  Li, Yuan ^a,b   Yang, Xiaoping ^a   Su, Lih Jen ^a   Flaig, Thomas W ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; FOCAL ADHESION KINASE; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; TETRAZOLIUM; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ARTICLE; BLADDER CANCER; CANCER CELL; CELL VIABILITY; CLONOGENIC ASSAY; COLONY FORMATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; ONCOGENE C KIT; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 79959723256     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2011.02.041     Document Type: Article

References (26)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. H. von der Maase, L. Sengelov, and J.T. Roberts Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 2005 4602460 4602468
3. C.N. Sternberg, A. Yagoda, and H.I. Scher Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium J Urol 133 1985 403 407 (Pubitemid 15129797)
4. M. Hussain, U. Vaishampayan, and W. Du Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer J Clin Oncol 19 2001 2527 2533 (Pubitemid 32391224)
5. J.A. McCaffrey, S. Hilton, and M. Mazumdar Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma J Clin Oncol 15 1997 1853 1857 (Pubitemid 27209514)
6. B.J. Gitlitz, C. Baker, and Y. Chapman A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma Cancer 98 2003 1863 1869 (Pubitemid 37310229)
7. N. Ferrara, R.D. Mass, C. Campa, and R. Kim Targeting VEGF-A to treat cancer and age-related macular degeneration Annu Rev Med 58 2007 491 504 (Pubitemid 46706529)
8. W. Wu, X. Shu, and H. Hovsepyan VEGF receptor expression and signaling in human bladder tumors Oncogene 22 2003 3361 3370 (Pubitemid 36713733)
9. E. Herrmann, E. Eltze, and S. Bierer VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer: relationships to clinicopathological parameters and long-term survival Anticancer Res 27 2007 3127 3133 (Pubitemid 47607535)
10. G. Xia, S.R. Kumar, and D. Hawes Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer J Urol 175 2006 1245 1252
11. G. Sonpavde, and H.T.E. Pazopanib A novel multitargeted tyrosine kinase inhibitor Curr Oncol Rep 9 2007 115 119 (Pubitemid 46332383)
12. R. Kumar, V.B. Knick, and S.K. Rudolph Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity Mol Cancer Ther 6 2007 2012 2021 (Pubitemid 47052491)
13. H. Hurwitz, A. Dowlati, and S. Savage Safety, tolerability, and pharmacokinetics of oral administration of GW780634 in pts with solid tumors J Clin Oncol 23 Suppl 16S 2005 3012
14. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27 55
15. W. Risau Mechanisms of angiogenesis Nature 386 1997 671 674 (Pubitemid 27193480)
16. K. Podar, G. Tonon, and M. Sattler The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma Proc Natl Acad Sci U S A 103 2006 19478 19483 (Pubitemid 46026056)
17. T.E. Hutson, and R.A. Figlin Evolving role of novel targeted agents in renal cell carcinoma Oncol Williston Park 21 2007 1175 1180 (Pubitemid 47463373)
18. A.A. Kamat, T.J. Kim, and C.N. Landen Jr. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer Cancer Res 67 2007 281 288 (Pubitemid 46142786)
19. J. Murtagh, H. Lu, and E.L. Schwartz Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation Cancer Res 66 2006 8192 8199 (Pubitemid 44299187)
20. T. Veikkola, M. Karkkainen, and L. Claesson-Welsh Regulation of angiogenesis via vascular endothelial growth factor receptors Cancer Res 60 2000 203 212 (Pubitemid 30070735)
21. A. Toker, and M. Yoeli-Lerner AKT signaling and cancer: surviving but not moving on Cancer Res 66 2006 3963 3966
22. J. Brognard, A.S. Clark, Y. Ni, and P.A. Dennis Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation Cancer Res 61 2001 3986 3997 [PubMed] (Pubitemid 32720961)
23. S. Banerjee, M. Hussain, and Z. Wang In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and Taxotere combination in prostate cancer Cancer Res 67 2007 3818 3826 (Pubitemid 46762169)
24. H. Abedi, and I. Zachary Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells J Biol Chem 272 1997 15442 15451 (Pubitemid 27255570)
25. S.K. Mitra, D. Mikolon, and J.E. Molina Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors Oncogene 25 2006 5969 5984 (Pubitemid 44477291)
26. P.M. Siesser, and S.K. Hanks The signaling and biological implications of FAK overexpression in cancer Clin Cancer Res 12 2006 3233 3237